Risk and Predictors for Early Radiation Pneumonitis in Patients with Stage III Non-small Cell Lung Cancer Treated with Concurrent or Sequential Chemoradiotherapy

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2014 Jul 31

PMID 25074618

Citations 28

Authors

Jun Dang

Guang Li

Shuang Zang

Shuo Zhang

Lei Yao

Affiliations

Soon will be listed here.

Abstract

Background: The rate of radiation pneumonitis (RP) for patients receiving chemoradiotherapy has been various across studies. Whether it is related to different chemotherapy schedules used in combination with radiation therapy were evaluated in this study. New factors associated with RP were also investigated.

Methods And Materials: A total of 369 consecutive patients with Stage III non small cell lung cancer treated with chemoradiotherapy were followed after radiotherapy (RT). Among them 262 patients received concurrent chemoradiotherapy followed by consolidation chemotherapy and 107 patients received only sequential chemotherapy after RT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0.

Results: The rate of grade ≥ 2 were 39.7%, 31% and 33.6% in the concurrent DP (docetaxel/cisplatin), concurrent NP (vinorelbine/cisplatin) and sequential group, and grade ≥ 3 RP were 18.4%, 9.5%, and 11.2% respectively. The rate of grade ≥ 3 RP was significantly higher in concurrent DP group than that in concurrent NP group (p = 0.04). RP occurred earlier in concurrent DP group than that in the other two groups. There were no significant differences in response rate among the three groups. In the multivariate analysis, age (OR = 1.99, p = 0.038 and OR = 8.90, p < 0.001), chemotherapy schedule (OR = 1.45, p = 0.041 and OR = 1.98, p = 0.013), mean lung dose(OR = 1.42, p < 0.001 and OR = 1.64, p < 0.001), and planning target volume(OR = 1.004, p = 0.001 and OR = 1.005, p = 0.021) were predictors for both grade ≥ 2 and grade ≥ 3 RP. Response to treatment was a new predictor for grade ≥ 3 RP only (OR = 4.39, p = 0.034).

Conclusions: Response to treatment was found to be a new predictor for grade ≥ 3 RP. Compared to concurrent NP schedule, concurrent DP schedule achieved similar response to treatment but resulted in a higher risk of grade ≥ 3 RP.

Citing Articles

Three-dimensional conformal radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: protocol for a systematic review and meta-analysis.

Huang X, Chen Q, Ren Y, Zhu J, Xu L, Huang S BMJ Open. 2024; 14(11):e090728.

PMID: 39515858 PMC: 11552014. DOI: 10.1136/bmjopen-2024-090728.

Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy.

Gunnarsson K, Movik L, Pettersson N, Back A, Nyman J, Hallqvist A Acta Oncol. 2024; 63:791-797.

PMID: 39415565 PMC: 11495145. DOI: 10.2340/1651-226X.2024.40576.

Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: A real-world single-center study in the pre-durvalumab era.

Zhu H, Xu Y, Gao H, Fan X, Fan M, Zhao K Cancer Med. 2024; 13(15):e70051.

PMID: 39082888 PMC: 11289899. DOI: 10.1002/cam4.70051.

A dynamic nomogram predicting symptomatic pneumonia in patients with lung cancer receiving thoracic radiation.

Zha Y, Zhang J, Yan X, Yang C, Wen L, Li M BMC Pulm Med. 2024; 24(1):99.

PMID: 38409084 PMC: 10895758. DOI: 10.1186/s12890-024-02899-w.

Adaptive Lung Radiation Therapy in the Era of Immunotherapy: A Single-Center Retrospective Study.

Portal D, Lu S, Piperdi H, Jabbour S, Reyhan M Adv Radiat Oncol. 2024; 9(1):101315.

PMID: 38260217 PMC: 10801661. DOI: 10.1016/j.adro.2023.101315.

References

Fournel P, Robinet G, Thomas P, Souquet P, Lena H, Vergnenegre A . Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01.... J Clin Oncol. 2005; 23(25):5910-7. DOI: 10.1200/JCO.2005.03.070. View

Huang E, Hope A, Lindsay P, Trovo M, El Naqa I, Deasy J . Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol. 2010; 50(1):51-60. PMC: 4041523. DOI: 10.3109/0284186X.2010.521192. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Palma D, Senan S, Tsujino K, Barriger R, Rengan R, Moreno M . Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2012; 85(2):444-50. PMC: 3448004. DOI: 10.1016/j.ijrobp.2012.04.043. View

Rodrigues G, Lock M, DSouza D, Yu E, Van Dyk J . Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiother Oncol. 2004; 71(2):127-38. DOI: 10.1016/j.radonc.2004.02.015. View

Curran Jr W, Paulus R, Langer C, Komaki R, Lee J, Hauser S . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19):1452-60. PMC: 3186782. DOI: 10.1093/jnci/djr325. View

Eroglu C, Orhan O, Unal D, Dogu G, Karaca H, Dikilitas M . Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer. Ann Thorac Med. 2013; 8(2):109-15. PMC: 3667439. DOI: 10.4103/1817-1737.109824. View

Onishi H, Kuriyama K, Yamaguchi M, Komiyama T, Tanaka S, Araki T . Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer. 2003; 40(1):79-84. DOI: 10.1016/s0169-5002(02)00532-9. View

Auperin A, Le Pechoux C, Rolland E, Curran W, Furuse K, Fournel P . Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13):2181-90. DOI: 10.1200/JCO.2009.26.2543. View

10.

Dang J, Li G, Lu X, Yao L, Zhang S, Yu Z . Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. J Cancer Res Clin Oncol. 2010; 136(8):1169-78. DOI: 10.1007/s00432-010-0764-4. View

11.

Gandara D, Chansky K, Albain K, Leigh B, Gaspar L, Lara Jr P . Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol. 2003; 21(10):2004-10. DOI: 10.1200/JCO.2003.04.197. View

12.

Graves P, Siddiqui F, Anscher M, Movsas B . Radiation pulmonary toxicity: from mechanisms to management. Semin Radiat Oncol. 2010; 20(3):201-7. DOI: 10.1016/j.semradonc.2010.01.010. View

13.

Wang S, Liao Z, Wei X, Liu H, Tucker S, Hu C . Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006; 66(5):1399-407. DOI: 10.1016/j.ijrobp.2006.07.1337. View

14.

Dillman R, Herndon J, Seagren S, Eaton Jr W, Green M . Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996; 88(17):1210-5. DOI: 10.1093/jnci/88.17.1210. View

15.

Phernambucq E, Spoelstra F, Verbakel W, Postmus P, Melissant C, Maassen van den Brink K . Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann Oncol. 2010; 22(1):132-138. DOI: 10.1093/annonc/mdq316. View

16.

Sunyach M, Falchero L, Pommier P, Perol M, Arpin D, Vincent M . Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2000; 48(2):459-63. DOI: 10.1016/s0360-3016(00)00618-0. View

17.

Xu Y, Ma S, Ji Y, Sun X, Jiang H, Chen J . Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lung Cancer. 2010; 72(3):327-32. DOI: 10.1016/j.lungcan.2010.09.012. View

18.

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M . Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83(6):417-23. DOI: 10.1093/jnci/83.6.417. View

19.

Bastos B, Hatoum G, Walker G, Tolba K, Takita C, Gomez J . Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2010; 5(4):533-9. DOI: 10.1097/JTO.0b013e3181ce3e00. View

20.

Belani C, Choy H, Bonomi P, Scott C, Travis P, Haluschak J . Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005; 23(25):5883-91. DOI: 10.1200/JCO.2005.55.405. View